Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11122001 | 0.93 | TSHR (0.41) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL21570869 | 0.84 | TSHR (0.48) | TSHRALDH1A1ACHECYP3A4NPC1 | |
| SCHEMBL12975855 | 0.83 | TSHR (0.37) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL2056762 | 0.82 | TSHR (0.52) | TSHRALDH1A1ACHECYP3A4 | |
| SCHEMBL2116165 | 0.82 | — | — | |
| SCHEMBL3686781 | 0.80 | — | — | |
| SCHEMBL21787200 | 0.78 | ACHE (0.41) | TSHRALDH1A1ACHECYP3A4NPC1 | |
| SCHEMBL27803239 | 0.78 | KDM4E (0.40) | TSHRALDH1A1ACHESMN1; SMN2 | |
| SCHEMBL640238 | 0.78 | THRB (0.52) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL5924841 | 0.77 | HPGD (0.57) | TSHRALDH1A1ACHENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112930487-B | Ophthalmic device | 鲍希与洛姆伯股份有限公司 | 2024-07-02 | — | — | CN | claimed |
| EP-3834017-A1 | HIGH WATER CONTENT OPHTHALMIC DEVICES | Bausch & Lomb Incorporated (US) | 2021-06-16 | — | — | EP | claimed |
| US-10816698-B2 | High water content ophthalmic devices | BAUSCH & LOMB INCORPORATED (US) | 2020-10-27 | — | — | US | claimed |
| US-10668676-B2 | Ophthalmic devices | BAUSCH & LOMB INCORPORATED (US) | 2020-06-02 | — | — | US | claimed |
| US-20200049857-A1 | HIGH WATER CONTENT OPHTHALMIC DEVICES | SALIX PHARMACEUTICALS, LTD. | 2020-02-13 | — | — | US | claimed |
| WO-2020032972-A1 | HIGH WATER CONTENT OPHTHALMIC DEVICES | BAUSCH & LOMB INCORPORATED (US) | 2020-02-13 | — | — | WO | claimed |
| US-20200047437-A1 | OPHTHALMIC DEVICES | MEDICIS PHARMACEUTICAL CORPORATION | 2020-02-13 | — | — | US | claimed |
| EP-3818401-B1 | WATER EXTRACTABLE OPHTHALMIC DEVICES | BAUSCH & LOMB (US) | 2024-10-30 | — | — | EP | disclosed |
| CN-112352170-B | Water extractable ophthalmic device | 鲍希与洛姆伯股份有限公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-112513681-B | Water extraction ophthalmic device | 鲍希与洛姆伯股份有限公司 | 2024-07-26 | — | — | CN | disclosed |
| EP-4396616-A1 | OPHTHALMIC DEVICES | Bausch + Lomb Ireland Limited (IE) | 2024-07-10 | — | — | EP | disclosed |
| CN-112930487-B | Ophthalmic device | 鲍希与洛姆伯股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-11897985-B2 | Water extractable ophthalmic devices | BAUSCH & LOMB INCORPORATED (US) | 2024-02-13 | — | — | US | disclosed |
| US-7901073-B2 | Silicone hydrogel with composite hydrophilic and silicone polymers prepared with selective crosslink agents | BAUSCH & LOMB INCORPORATED (US) | 2011-03-08 | — | — | US | disclosed |
| WO-2010147864-A2 | BIOMEDICAL DEVICES | BAUSCH & LOMB INCORPORATED (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100315588-A1 | Biomedical devices | BAUSCH & LOMB INCORPORATED (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100315588-A1 | Biomedical devices | BAUSCH & LOMB INCORPORATED (US) | 2010-12-16 | — | — | US | disclosed |
| EP-2167555-A1 | CROSSLINK AGENTS AND DUAL RADICAL CURE POLYMER | Bausch & Lomb Incorporated (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090018233-A1 | Crosslink Agents and Dual Radical Cure Polymer | SOLTA MEDICAL, INC. | 2009-01-15 | — | — | US | disclosed |
| WO-2009009527-A1 | CROSSLINK AGENTS AND DUAL RADICAL CURE POLYMER | BAUSCH & LOMB INCORPORATED (US) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018233-A1 | Crosslink Agents and Dual Radical Cure Polymer | UACA, CRYAA, RAD51 | TSHR 2555/4885ALDH1A1 1327/4885TP53 3048/4885 |
| US-20200049857-A1 | HIGH WATER CONTENT OPHTHALMIC DEVICES | TCOF1, WDR1, UACA | TSHR 1148/4885ALDH1A1 3002/4885TP53 2352/4885 |
| US-10816698-B2 | High water content ophthalmic devices | TCOF1, WDR1, UACA | TSHR 1148/4885ALDH1A1 3002/4885TP53 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.